{
  "source": "PA-Notification-Fruzaqla.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1435-2\nProgram Prior Authorization/Notification\nMedication Fruzaqla™ (fruquintinib)\nP&T Approval Date 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nFruzaqla™ (fruquintinib) is a kinase inhibitor indicated for the treatment of adult patients with\nmetastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-,\noxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type\nand medically appropriate, an anti-EGFR therapy.\nThe National Comprehensive Cancer Network (NCCN) also recommends use of Fruzaqla for\nadvanced colorectal cancer in patients who have progressed through all available regimens\nbesides regorafenib or trifluridine/tipiracil with or without bevacizumab.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Fruzaqla will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Colorectal Cancer\n1. Initial Authorization\na. Fruzaqla will be approved based on the following criteria:\n(1) Diagnosis of colorectal cancer\n-AND-\n(2) Disease is one of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(a) Advanced\n(b) Metastatic\n-AND-\n(3) Patient has been previously treated with all of the following:\n(a) Fluoropyrimidine-based chemotherapy (e.g., capecitabine, 5-FU)\n(b) Oxaliplatin-based chemotherapy (e.g., CAPEOX, FOLFOX)\n(c) Irinotecan-based chemotherapy (e.g",
    "y treated with all of the following:\n(a) Fluoropyrimidine-based chemotherapy (e.g., capecitabine, 5-FU)\n(b) Oxaliplatin-based chemotherapy (e.g., CAPEOX, FOLFOX)\n(c) Irinotecan-based chemotherapy (e.g., FOLFIRI, FOLFIRINOX)\n(d) Anti-VEGF therapy (e.g., aflibercept, bevacizumab, ramucirumab)\n-AND-\n(4) One of the following:\n(a) Both of the following:\ni. Disease is RAS wild-type\n-AND-\nii. Patient has been previously treated with an anti-EGFR therapy (e.g.,\ncetuximab, panitumumab)\n-OR-\n(b) Disease is not RAS wild-type\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fruzaqla will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Fruzaqla therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\n© 2025 UnitedHealthcare Services, Inc.\n2\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n4. References:\n1. Fruzaqla [package insert]. Lexington, MA: Taketa Pharmaceuticals America, Inc.; November\n2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed on December 20, 2024.\nProgram Prior Authorization/Notification – Fruzaqla (fruquintinib)\nChange Control\n2",
    "Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org. Accessed on December 20, 2024.\nProgram Prior Authorization/Notification – Fruzaqla (fruquintinib)\nChange Control\n2/2024 New program\n2/2025 Annual review with no changes to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}